寶鷹股份(002047.SZ):第三期員工持股計劃出售完畢暨終止
格隆匯11月12日丨寶鷹股份(002047.SZ)公佈,公司第三期員工持股計劃(以下簡稱“本員工持股計劃”)所持有的公司股票已全部出售完畢。
本員工持股計劃持有的公司股票7,595,885股(佔公司股本總額的0.5010%)已在2023年6月12日至2024年11月8日期間通過集中競價交易方式全部出售完畢。本員工持股計劃在實施期間,嚴格遵守了股票市場交易規則和中國證券監督管理委員會、深圳證券交易所關於信息敏感期不得買賣股票的規定,不存在利用內幕信息進行交易的情形。
根據《持股計劃(草案)》的相關規定,本員工持股計劃已實施完畢並終止,後續將進行資產清算及出資額返還等相關工作。第
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.